Moderna (MRNA) Revenue — Quarter Ended Jun 30, 2024
Revenue increased compared to the immediately preceding quarter. However, revenue declined compared to the same quarter one year earlier.
Key takeaway
Quarter ended Jun 30, 2024 · FY2024 Q2
Revenue increased compared to the immediately preceding quarter. However, revenue declined compared to the same quarter one year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$241M
Revenue reported for this quarter.
Quarter-over-quarter
+44.3%
Change from the immediately preceding quarter.
Year-over-year
-29.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$5.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2023 | $1.8B | -45.6% |
| Dec 31, 2023 | $2.8B | -44.7% |
| Mar 31, 2024 | $167M | -91.0% |
| Jun 30, 2024 | $241M | -29.9% |
Revenue performance
The reported revenue for the quarter moved upward from the prior quarter, reversing the sharp decline seen in the previous period.
Quarterly comparison
Compared to the immediately preceding quarter, revenue rose. Compared to the same quarter one year ago, revenue was lower.
What to watch
The filing context does not provide specific commentary on revenue drivers for this quarter.